View Author
Nunen, A.B. van
( A.B. van Nunen)
therapy patient hepatitis lamivudine hbsag hepatitis b combination hbeag combination therapy level study virus antibody hbeag seroconversion treatment seroconversion tuvirumab hbv dna anti-hb serum response infection effect lamivudine therapy monotherapy phase relapse interferon result lamivudine monotherapy group hepatology hepatitis b virus baseline trial complex assay hepatitis b patients schalm sw ifn therapy hepatitis b infection antigen chapter hbv dna levels schalm efficacy analysis follow-up liver 16 weeks hbsag levels sample man ra lamivudine-ifn combination therapy replication reduction model pre-treatment detection limit factor figure table inhibition pretreatment interferon alfa hbv patients vaccine hbv dna negativity administration eurohep regression infusion month production hepatol decline activity clearance thomas hc
3 Most Recent Publications
|
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase
(Article)
Nunen, A.B. van Schalm, S.W. Man, R.A. de Hansen, B.E. Suh, D.J. Lohr, H.F. Chemello, L. Fontaine, H. Heathcote, J. Song, B.C. Janssen, H.L.A. |
2003-01-01
|
|
Immune modulation in chronic hepatitis B patients
(Doctoral Thesis)
Nunen, A.B. van |
2002-10-23
|
|
Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: Monitoring of serum TUVIRUMAB in immune complexes.
(Article)
Heijtink, R.A. Osterhaus, A.D.M.E. Man, R.A. de Bergen, P. van Östberg, L. Nunen, A.B. van |
2001-01-01
|
